PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals reported another quarter of operating losses as it advances its lead cancer drug rezatapopt. For the three months ended March 31, 2026, the company posted a net loss of $18.0 million, similar to the prior-year loss of $17.4 million, as it remains in clinical development with no product revenue.
Research and development expense fell to $15.3 million from $17.4 million, mainly from lower contract research costs on rezatapopt, while general and administrative expense declined to $3.7 million. Interest income decreased to $1.0 million from $1.9 million due to lower balances and rates.
Cash, cash equivalents, and marketable securities totaled $93.5 million, and management believes this will fund operations until the end of the second quarter of 2027. The company highlighted ongoing pivotal Phase 2 work in the PYNNACLE trial and noted that rezatapopt received Orphan Drug Designation in March 2026 for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancer, with plans to file a New Drug Application in the first quarter of 2027.
PMV Pharmaceuticals reported first quarter 2026 results and highlighted progress for its lead candidate rezatapopt. The company ended March 31, 2026 with $93.5 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the end of the second quarter of 2027. Net loss was $18.0 million, or $0.34 per share, roughly in line with the prior year as both research and development and general and administrative expenses declined.
Clinically, updated Phase 2 PYNNACLE data in platinum‑resistant/refractory ovarian cancer with TP53 Y220C mutations showed an overall response rate of 44% (32/72) by RECIST 1.1, rising to 46% (34/74) including two additional unconfirmed partial responses, with a median response duration of 8.2 months. Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C‑positive ovarian, fallopian tube, and primary peritoneal cancers, and PMV plans to submit a New Drug Application for this ovarian cancer indication in the first quarter of 2027.
PMV Pharmaceuticals, Inc. Amendment No. 3 to a Schedule 13G/A reports that Sio Capital Management, LLC beneficially owned 3,076,580 shares of common stock, representing 5.77% of the class. The filing states these shares are held with shared voting and dispositive power as of March 31, 2026. The filing cites 53,329,392 shares outstanding as of March 6, 2026 from the issuer's Form 10-K. The statement is signed by the Reporting Person's Chief Compliance Officer on May 4, 2026.
PMV Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026 at 10:00 a.m. Eastern. Investors will elect two Class III directors, David H. Mack, Ph.D. and Laurie Stelzer, approve on a non-binding basis executive pay, and ratify Ernst & Young LLP as auditor for 2026.
The company will reduce its board from seven to six members as chair Richard Heyman, Ph.D. departs, and plans for director Laurie Stelzer to become board chair while David Mack remains CEO. The proxy describes Nasdaq independence compliance, committee structures, ESG oversight and detailed director compensation.
The filing also reviews 2025 executive pay, including total 2025 compensation of $1.7 million for CEO David Mack, and explains the prior 2025 say-on-pay failure, linking stockholder concerns mainly to a 2024 employee-only option exchange the board views as a one-time event.
PMV Pharmaceuticals, Inc. Chief Financial Officer Michael Carulli reported an equity compensation grant and updated his share holdings. He received an employee stock option for 240,000 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.
The option vests in 48 equal monthly installments beginning on April 5, 2026, which means the award vests gradually over four years. Following this filing, Carulli directly holds 73,848 shares of common stock, which includes 13,702 shares acquired under the company’s Employee Stock Purchase Plan on November 20, 2025.
PMV Pharmaceuticals reported that its General Counsel & COO, Robert Ticktin, received a grant of 319,270 employee stock options. These options give him the right to buy PMV Pharmaceuticals stock in the future, rather than representing shares bought on the open market.
The options were granted at an exercise price listed as $0.0000 per share in the filing and will vest over time. According to the footnote, the award vests in 48 equal monthly installments beginning on April 3, 2026, meaning the executive gains the right to exercise portions of the grant gradually over four years.
PMV Pharmaceuticals, Inc. reported that Chief Development Officer Deepika Jalota received an employee stock option grant. The award covers 303,310 options to purchase company stock and is classified as a grant or award acquisition. According to the terms, these options begin vesting on April 5, 2026, in 48 equal monthly installments, meaning the award vests gradually over four years, which is designed to align the executive’s incentives with the company’s longer-term performance.
PMV Pharmaceuticals, Inc. granted President and CEO David Henry Mack an employee stock option covering 744,960 shares of common stock. The award was reported as an acquisition of derivative securities at a stated price of 0.0000 per share. These options vest in 48 equal monthly installments beginning on April 5, 2026, providing long-term, time-based equity compensation tied to his continued service.
PMV Pharmaceuticals, Inc. reported full-year 2025 results and highlighted progress for its lead p53 reactivator, rezatapopt. The Phase 2 PYNNACLE trial showed a 34% overall response rate among 103 evaluable patients and a 46% response rate in 48 ovarian cancer patients, with responses lasting around 8 months.
Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancers, and Phase 1 data were published in the New England Journal of Medicine. As of December 31, 2025, PMV held $112.9 million in cash, cash equivalents, and marketable securities, providing expected cash runway to the end of the second quarter of 2027.
Net loss for 2025 was $77.7 million versus $58.7 million in 2024, driven mainly by higher research and development spending of $69.9 million. General and administrative expenses decreased to $16.3 million from $26.9 million, reflecting lower facility and personnel costs after prior-year restructuring.